Home > Neurology > EAN 2019 > Letter from the Editor

Letter from the Editor

Prof. Hans-Peter Hartung, Heinrich-Heine-University Düsseldorf, Germany
EAN 2019
Dear Reader,

Inflammatory processes are involved in the etiopathology of most neurological diseases, even for conditions previously considered as 'non-inflammatory’ such as Alzheimer’s disease, ALS, epilepsy, movement disorders, stroke, and migraine.

With neuroinflammation as the overarching theme, the European Academy of Neurology held its 5th annual meeting in Oslo. It provided a forum for researchers, clinician scientists, and practising neurologists. Cutting-edge research related to elucidating the etiopathogenesis were presented, as well as results of new treatment trials for neurological conditions across the board.

This peer-reviewed conference report summarises the highlights from the programme. We hope you will find these mini-reviews useful.

Yours sincerely,

Hans-Peter Hartung


Prof. Hartung has been Chair of the Department of Neurology at Heinrich-Heine-University in Düsseldorf since 2001. He is also Director of the Center of Neuropsychiatry and the Department of Conservative Medicine at University Hospital Düsseldorf.

He studied medicine at the Universities of Düsseldorf, Glasgow, Oxford, and London. After graduation he served an immunology fellowship at the University of Mainz.

Prof. Hartung’s clinical and translational research interests are in the field of basic and clinical neuroimmunology and in particular multiple sclerosis and immune neuropathies. He has been involved as steering committee member in multiple clinical trials of new drugs for the treatment of multiple sclerosis, Guillain-Barre syndrome, and chronic inflammatory demyelinating polyneuropathy.

Prof. Hartung is a former President of ECTRIMS.


Hans-Peter Hartung has received fees for consulting, speaking, and serving on steering committees from Bayer Healthcare, Biogen, GeNeuro, MedImmune, Merck, Novartis, Opexa, Receptos Celgene, Roche, Sanofi Genzyme, CSL Behring, Octapharma, and Teva, with approval by the Rector of Heinrich-Heine-University.

Posted on